EHA Expert Interview | Professor Hongyan Tong: New MDS Classification and Advances in the MDS-f Subtype

EHA Expert Interview | Professor Hongyan Tong: New MDS Classification and Advances in the MDS-f Subtype

2024.09.13
The 29th European Hematology Association (EHA) Annual Meeting was grandly held in Madrid, Spain, from June 13-16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world every year to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, the latest classification standards and clinical research outcomes for MDS received widespread attention. "Oncology Frontier - Hematology Frontier" invited Professor Hongyan Tong from The First Affiliated Hospital, Zhejiang University School of Medicine to provide an in-depth interpretation of the key updates in the latest WHO MDS classification standards and share her team's groundbreaking research achievements in MDS, particularly in the MDS-f subtype.
Professor Baohui Han: Strategically Analyzing ASCO’s ADC Developments in NSCLC and Planning for Future Progress

Professor Baohui Han: Strategically Analyzing ASCO’s ADC Developments in NSCLC and Planning for Future Progress

2024.09.13
On July 2, 2024, the "ADC High-Level Closed-Door Seminar," chaired by Vice President Yong Yang of China Pharmaceutical University and President Jin Li of Shanghai Gaobo Oncology Hospital, was grandly held in Shanghai. The seminar explored the current status and future of ADC development. During the event, Oncology Frontier interviewed Professor Baohui Han from the Shanghai Chest Hospital . Combining recent ASCO conference updates, Professor Han analyzed the efficacy results and safety management points of ADC treatment in NSCLC and shared insights on the future prospects of ADC development.
EHA China’s Voice丨A New Perspective on Immune Escape in AML: Dr. Yang Liang’s Team Unveils the Regulatory Mechanism of FLT3-ITD

EHA China’s Voice丨A New Perspective on Immune Escape in AML: Dr. Yang Liang’s Team Unveils the Regulatory Mechanism of FLT3-ITD

2024.09.13
The 29th Annual Congress of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from all over the world every year to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, a study by Dr. Yang Liang from Sun Yat-sen University Cancer Center was selected for poster presentation, exploring how FLT3-ITD promotes immune escape in AML cells by up-regulating CD47 expression and reducing the phagocytic ability of macrophages. To provide insight into these research findings, "Oncology Frontier-Hematology Frontier" invited Dr. Yang Liang to give us a brief introduction to the study.
Professor Qian Jiang: Exploring New Models of Regional Academic Exchange, Beijing Hematology Academic Annual Meeting Concludes Successfully

Professor Qian Jiang: Exploring New Models of Regional Academic Exchange, Beijing Hematology Academic Annual Meeting Concludes Successfully

2024.09.13
On July 5th, the 17th Beijing Hematology Academic Annual Meeting, hosted by the Beijing Medical Association Hematology Branch, concluded successfully in Beijing. This year's meeting featured innovative and unique formats and rich content, providing a platform for participants to share cutting-edge advancements and experiences. It also showcased the original research achievements in the field of hematology in Beijing. "Oncology Frontier - Hematology Frontier" invited Professor Qian Jiang, the current chair of the Beijing Medical Association Hematology Branch, the main organizer of this conference, and a professor at Peking University People's Hospital, to share the highlights and unique aspects of the meeting and to discuss its far-reaching impacts on the future.
Dr. Xiaoyu Zhu and Dr. Aijie Huang on the Efficacy and Safety of TPO Receptor Agonists for Treating Thrombocytopenia Post-Cord Blood Transplantation

Dr. Xiaoyu Zhu and Dr. Aijie Huang on the Efficacy and Safety of TPO Receptor Agonists for Treating Thrombocytopenia Post-Cord Blood Transplantation

2024.09.13
At the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) conference, the research team led by Dr. Xiaoyu Zhu and Dr. Aijie Huang from The First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital) garnered significant attention. Their study on the efficacy and safety of avatrombopag for treating thrombocytopenia following cord blood transplantation (UCBT) was selected for oral presentation (OC33.3), with Dr. Huang delivering the report. This study not only showcases the exceptional capabilities of Chinese research teams in hematology but also contributes valuable insights to the global hematology community. "Oncology Frontier - Hematology Frontier" had an exclusive interview with Dr. Aijie Huang to delve deeper into the research and discuss future plans in the field of UCBT.
Dr. Baohui Han Analyzes the Relationship Between PD-L1 Expression and Crizotinib Efficacy in ROS-1 Fusion-Positive NSCLC

Dr. Baohui Han Analyzes the Relationship Between PD-L1 Expression and Crizotinib Efficacy in ROS-1 Fusion-Positive NSCLC

2024.09.12
The development of modern oncology has provided a variety of groundbreaking treatment options for lung cancer, making it one of the most rapidly evolving solid tumors. To help clinical physicians gain an in-depth and comprehensive understanding of the significant advancements in this field, "Oncology Frontier" has joined forces with Dr. Hua Zhong and Dr. Baohui Han, Director of the Department of Respiratory and Critical Care Medicine at Shanghai Jiao Tong University School of Medicine Affiliated Chest Hospital,  to create a clinical progress series called "Zhong's Insights, Hui's Wisdom." By interpreting high-quality clinical studies in the field of lung cancer, this series aims to promote the improvement of clinical diagnostic and treatment practices. In this 23rd issue of the “Zhong's Insights, Hui's Wisdom” series, Dr. Hua Zhong and Dr. Baohui Han provide their expert analysis on the relationship between PD-L1 expression levels and the efficacy of first-line crizotinib treatment in ROS-1 fusion-positive non-small cell lung cancer (NSCLC) patients. The study was published in Lung Cancer by the Department of Respiratory and Critical Care Medicine at Shanghai Jiao Tong University School of Medicine Affiliated Chest Hospital, with Dr. Runbo Zhong as the corresponding author.
Eur Urol | Biomarkers in Prostate Cancer Screening: Sometimes, “More Is Better”

Eur Urol | Biomarkers in Prostate Cancer Screening: Sometimes, “More Is Better”

2024.09.12
Prostate cancer is one of the most common malignancies in men, and the widespread use of prostate-specific antigen (PSA) testing has significantly improved early diagnosis rates. However, a series of prostate cancer screening trials in Europe have found that PSA-based screening benefits only a subset of patients. How can more prostate cancer patients benefit from screening? Are there other biomarkers that can be used for screening? A recent article published in European Urology discusses these questions. We have summarized the key points for our readers.
WCLC 2024 | Global Survey: Barriers to Optimal Biomarker Testing for Lung Cancer

WCLC 2024 | Global Survey: Barriers to Optimal Biomarker Testing for Lung Cancer

2024.09.12
The 2024 World Conference on Lung Cancer (WCLC) will be held in San Diego, USA, from September 7-10. Dr. Matthew Smeltzer, Associate Professor , Division of Epidemiology, Biostatistics, and Environmental Health at the University of Memphis, Tennessee, will present the analysis of the "2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing" in an oral session titled "OA03 Predicting the Future: New Pathology Assessments and Imaging Biomarkers."
Annual Review | Academician Xu Zhang: Chinese Doctors Leading a New Revolution in Urological Surgery Innovation

Annual Review | Academician Xu Zhang: Chinese Doctors Leading a New Revolution in Urological Surgery Innovation

2024.09.11
Time rewards those who strive, and success comes to those who persevere. As 2023 draws to a close, the year has left behind many noteworthy achievements in China’s field of urology, especially in the areas of prostate cancer surgery and drug treatments. On this occasion, Urology Frontier interviewed Xu Zhang, Academician of the Chinese PLA General Hospital and a pioneer in laparoscopic techniques in China’s urological surgery. In this interview, he shared significant developments in surgical and medical treatments for prostate cancer over the past year.
Academician Xu Zhang: “Nivolumab” Assists in UC Treatment, Filling the Gap in First-Line mUC Therapy, Leading the Era of Immunotherapy for UC

Academician Xu Zhang: “Nivolumab” Assists in UC Treatment, Filling the Gap in First-Line mUC Therapy, Leading the Era of Immunotherapy for UC

2024.09.11
At the 2023 ESMO Congress, the field of urothelial carcinoma (UC) witnessed a major breakthrough. The global multicenter Phase III CheckMate-901 study showed that in the first-line treatment of unresectable or metastatic urothelial carcinoma (mUC), nivolumab combined with cisplatin-based chemotherapy achieved dual positive results in the co-primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to standard cisplatin chemotherapy (Abstract LBA7). This is the first regimen in nearly 30 years to demonstrate significantly superior survival benefits over cisplatin chemotherapy in this field. Urology Frontier invited Academician Xu Zhang, the Chair-elect of the Urology Branch of the Chinese Medical Association (CUA) and from the Chinese PLA General Hospital, to discuss the general incidence, current diagnosis and treatment status, and recent advances in UC. He also provided an interpretation of the significant immunotherapy study results.